We are international
Donate
TEXT SIZE   


ASH 2012: Dr. Usmani- Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)
Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, AR
12.03.12


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles